ARCHIVES

Advocates Oppose Proposals to Market Drugs After Phase I.

This article is from The Cancer Letter archive.

Vol. 32 No. 22 | June 9, 2006

Download PDF Visit The Full Archive

Related Articles

Study: Vismodegib Effective Where Surgery is Inappropriate

June 24, 2011

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

September 27, 2013

Rabson Replaces Berlin At Div. Of Biology, Diagnosis

February 14, 1975

Realities Of The 1989 Budget: Number Of grants Cut By 250, Only 255 Of Approved Will By Funded

October 7, 1988

Professional Societies: ASCO opposes FDA On Stem Cell Transplant Regs

May 16, 1997

In Brief: NIH Reviewers, Advisors To Get Increase In Honoraria; Price Leaving NCI for Maryland

March 14, 1980